Pharmaceutical Product Development’s Senior Secured Credit Facilities
August 20, 2015
On August 18, 2015, Pharmaceutical Product Development, LLC (“PPD”), a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services, closed a dividend recapitalization transaction. Cravath represented Credit Suisse as lead arranger in connection with the arrangement of $2.875 billion of senior secured credit facilities. PPD is a portfolio company of The Carlye Group and Hellman & Friedman.
The Cravath team included partner Joseph D. Zavaglia and associates Matthew G. Jones and Sean M. Gholz. Summer associate Nathan H. Trunnell also worked on this matter.
Related Practices & Industries
People
- Photo
-
-
J.D., 2004, Brooklyn Law SchoolValedictorian, summa cum laude
-
B.B.A., 2001, College of Insurancecum laude
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
July 06, 2026
UVEX’s Upsize and Repricing of its Term Loan Facility
Cravath represented the agent, mandated lead arrangers, and lenders in connection with the repricing of UVEX GROUP GmbH’s €400 million term loan facility and €50 million term loan add-on. UVEX GROUP GmbH is a portfolio company of Warburg Pincus. The transaction closed on June 19, 2026.
Deals & Cases
April 06, 2026
Versigent’s $1.35 Billion Credit Facilities and $1.6 Billion High‑Yield Senior Notes Offering in Connection with Aptiv PLC’s Spin‑Off of Versigent
Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $1.35 billion of credit facilities made available to subsidiaries of Versigent Limited, a global leader in the design, development and manufacture of low voltage and high voltage electrical architectures and the holding company for Aptiv PLC’s Electrical Distribution Systems segment, which Aptiv PLC spun off into a separate, independent, publicly traded company. The proceeds were used to partially finance the spin‑off. The credit facilities consisted of a $500 million term loan facility and an $850 million revolving credit facility. The transaction closed on November 26, 2025.
Deals & Cases
February 20, 2026
First Solar’s $1.5 Billion Revolving Credit Facility
Cravath represented First Solar, Inc. in connection with its $1.5 billion revolving credit facility. First Solar is America’s leading photovoltaic solar technology and manufacturing company, and the only US‑headquartered company among the world’s largest solar manufacturers. The transaction closed on February 13, 2026.
Deals & Cases
January 08, 2026
Genmab’s $3.5 Billion of Credit Facilities and Offering of $1.5 Billion Senior Secured Notes and $1 Billion Senior Unsecured Notes in Connection with its Acquisition of Merus
Cravath represented the administrative agent, joint lead arrangers and joint bookrunners in connection with $3.5 billion of credit facilities made available to Genmab, a leading international biotechnology company, and one of its wholly‑owned subsidiaries, Genmab Finance LLC, as part of the financing transactions undertaken in connection with its acquisition of Merus N.V., a leading oncology company developing innovative antibody therapeutics. The credit facilities consisted of a $2 billion term loan “B” facility, a $1 billion term loan “A” facility and a $500 million revolving credit facility. The transaction closed on December 12, 2025.
